Enquiry IconContact Us
CMI Logo

Human papillomavirus infection is most common sexually transmitted infection caused by HPV-related cancers such as cervical and genital cancer. Human papillomavirus infection vaccines are used to prevent genital wart, anal cancer, cervical cancer, and vaginal cancer. Three commercially available HPV prevention vaccine such as Gardasil and Gardasil 9 by Merck & Co., Inc. and Cervarix by GlaxoSmithKline plc, are proven to be highly effective in preventing of HPV infection and genital precancerous lesions. The adoption of preventive vaccines shifted the paradigm of diseases, and are expected to have a major impact in reducing the burden of cervical cancer, HPV-associated malignancies, and benign tumors. The key factors driving growth of the human papillomavirus infection vaccine market include large number of pipeline products, increasing research for therapeutic vaccine, governmental initiative for immunization program, and high prevalence of HPV-related infectious disease.

Human Papillomavirus (HPV) Infection Vaccines Market Driver

Large number of clinical trials conducted by pharmaceutical and biopharmaceutical companies are expected to fuel growth of the HPV infection vaccine market during the forecast period. For instance, Merck & Co., Inc., is conducting Phase III clinical trial for it quadrivalent human papillomavirus recombinant vaccine for type 6, 11, 16, and 18. Moreover, Shanghai Bovax Biotechnology Co., Ltd., is engaged in evaluating safety and primary immunogenicity of the quadrivalent human papillomavirus vaccine in female population of China. Currently studies are in phase I clinical trial. Furthermore, Serum Institute of India Pvt. Ltd., is developing tetravalent HPV vaccine, which is expected to provide protection of around 90% against HPV infections, which are prevalent in the emerging economies such as India and China.

Moreover, increasing research on therapeutic vaccine for treatment of HPV infection to address unmet medical need is expected to boost growth of the human papilloma virus (HPV) infection vaccines market. For instance, Profectus BioSciences, Inc., is engage in developing GeneVax prime/VesiculoVax, a therapeutic vaccine for HPV infection. The vaccine is expected to be effective against seven HPV types. Moreover, Inovio Pharmaceuticals, Inc., is investigating VGX-3100 as candidate for immunotherapy to demonstrate efficacy against cervical HSIL associated with HPV-16 and HPV-18. VGX-3100 is divalent DNA plasmid-based therapeutic vaccine, which completed phase 2b clinical trial in 2015 and initiated phase 3 in June 2017.

Governmental and non-governmental organization plays important role in increasing awareness through immunization program, in turn driving growth of the human papillomavirus infection vaccine market. For instance, in 2012, the Global Alliance for Vaccines and Immunization (GAVI) support for HPV vaccine introduction targeted to reach 30 million girls in emerging economies by 2020. In 2016, Joint UN Global Programme was set up for prevention of cervical cancer, which includes vaccination in high disease burden countries.

Furthermore, global HPV-related disease burden is expected to drive growth of the human papillomavirus (HPV) infection vaccines market. According to National Cancer Institute, 2015, HPV type 16 and type 18, causes around 70% of cervical cancer and is responsible for almost all cervical cancer. According to American Society of Clinical Oncology (ASCO), in 2017, an estimated 12,820 women in the U.S. are expected to be diagnosed with cervical cancer along with 4,210 deaths every year. According to World Health Organization (WHO), 2014, HPV type 6 and type 11 are responsible for 90% of the anogenital warts.

Human Papillomavirus (HPV) Infection Vaccines Market Restrains

The human papillomavirus infection vaccine market is expected to constrain by limited number of Food and Drug Administrations (FDA) approved commercial vaccines. High cost of vaccine development is also expected to hinder the human papillomavirus (HPV) infection vaccines market growth over the forecast period. Moreover, variable immunization coverage is estimated to impact the regional size. For instance, economies such as U.K and Mexico has 80% vaccination coverage whereas full-dosage coverage remains below 50% in France and in the U.S.

Human Papillomavirus (HPV) Infection Vaccines Market Regional Analysis

Regional segmentation of human papillomavirus (HPV) infection vaccine market by Coherent Market Insights, includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America comprises major share of the human papillomavirus infection treatment vaccine market, owing to high prevalence of cervical cancer, local market players and increasing governmental initiatives, followed by Europe. For instance, according to WHO 2016, currently 86% of America and 62% of European region girls have access to free HPV vaccination. Moreover, incidence of cervical cancer in Europe was 58,348 individuals per million in 2012. However, Asia Pacific is expected to witness significant growth during forecast period, due to awareness among the population for immunization.

Human Papillomavirus (HPV) Infection Vaccines Market Key Players

Major players operating in the HPV infection vaccine market include Merck & Co., Inc. and GlaxoSmithKline plc. The companies having the candidate for HPV vaccines are Shanghai Bovax Biotechnology Co., Ltd., Profectus BioSciences, Inc., 2A Pharma AB and ISA Pharmaceuticals.

Human Papillomavirus (HPV) Infection Vaccines Market - Taxonomy

By Product

  • Gardasil
  • Gardasil 9
  • Cervarix
  • Other Vaccines

By End Users

  • Hospitals
  • Clinics
  • Healthcare Centers
  • Other

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.

Data Triangulation Methodology | Coherent Market Insights

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Market Analysis | Coherent Market Insights

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Subscribe Newsletter

Kindly subscribe for our latest news & articles.